Published Clinical research on medical benefits of Psychedelics

Depression

Psilocybin-containing mushrooms, ayahuasca, and mescaline-containing cacti all have shown efficacy in reducing symptoms of depression.

Psilocybin Mushrooms

Frontiers in Psychiatry

Cross-Sectional Associations Between Lifetime Use of Psychedelic Drugs and Psychometric Measures During the COVID-19 Confinement: A Transcultural Study

Read more
Psilocybin Mushrooms

Frontiers in Psychiatry

Depression, Mindfulness, and Psilocybin: Possible Complementary Effects of Mindfulness Meditation and Psilocybin in the Treatment of Depression. A Review

Read more
Psilocybin Mushrooms

Frontiers in Pharmacology

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

Read more
Psilocybin Mushrooms

Journal of Psychopharmacology

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression

Read more
PSILOCYBIN MUSHROOMS

Scientific Reports

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

Read more
Mescaline Cacti

ACS Pharmacology

Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes

Read more
AYAHUASCA

Frontiers in Psychiatry

Cortisol Modulation by Ayahuasca in Patients With Treatment Resistant Depression and Healthy Controls

Read more
AYAHUASCA

Psychological Medicine

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial

Read more
SUPPORT OUR MOVEMENT

Help us raise money for our education & advocacy causes

Donate